Nektar abandons opioid drug after a unanimous 27-0 rebuff from FDA adcomm
Nektar had the wrong drug at the wrong time.
That was the implication from the FDA staff, who in briefing documents about Nektar’s oral opioid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
